Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Researchers publish new studies and findings in the area of cancer therapy
June 17th, 2005
New findings from Germany, the United States and Ireland describe advances in cancer therapy. Study 1: Tyrosine kinase inhibitor PTK/ZK retards VEGF-related tumor growth. According to recent research published in the journal Chembiochem, "the angiogenesis inhibitor PTK 787/ZK 222584 (PTK/ZK) blocks all known VEGF receptor (VEGFR) tyrosine kinases, including the lymphangiogenic VEGFR3, in the lower nanomolar range. From a panel of 100 kinases only platelet derived growth factor receptor (PDGFR), c-kit, and c-fms are inhibited beyond those in the nanomolar range." "PTK/ZK functions as a competitive inhibitor at the...
Source: Drug Week (2005-06-17)
|
